Pagina 3 - I migliori medici di Trapianto di midollo osseo - TOP-88medici

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Il medico è uno specialista rinomato in ematologia e trapiantologia, con una vasta esperienza nella gestione di casi complessi che coinvolgono disturbi del sangue e trapianti di organi. Il medico ha contribuito in modo significativo ai progressi in questi campi sia attraverso la pratica clinica che la ricerca. Con numerose pubblicazioni su riviste mediche di spicco, il medico è riconosciuto per aver sviluppato protocolli di trattamento innovativi e migliorato i risultati dei pazienti. Inoltre, il medico ha ricoperto vari ruoli di leadership in prestigiose istituzioni mediche, migliorando la qualità delle cure e dell'educazione in ematologia e trapiantologia.<\/p>

Il medico è capo del Dipartimento di Ematologia presso l'Hadassah Medical Center e professore specializzato in diagnostica molecolare delle malattie ematologiche, malattie del sangue maligne, trapianto di midollo osseo, terapia genica e immunologia. Dopo essersi laureato presso la Facoltà di Medicina dell'Università Ben-Gurion del Negev, il medico ha completato studi post-laurea presso il Memorial Sloan-Kettering Cancer Center. Nel 2017, il medico è diventato la prima donna a servire come Decano della Scuola di Medicina Hadassah. Il medico è membro di diverse società professionali, tra cui la Società Israeliana di Ematologia e la Società Internazionale di Emato-Oncologia.<\/p>

Con 20 anni di pratica, la dottoressa si specializza in ematologia e oncologia pediatrica, concentrandosi su malattie rare del cancro del sangue. Ha eseguito oltre 3.500 trapianti di midollo osseo, guadagnandosi una reputazione tra i pazienti come colei che "trapianta la vita."

La sua competenza e dedizione sono state riconosciute da Forbes, che l'ha nominata una delle migliori dottoresse nel 2018.

Il medico è specializzato in Ematologia e Oncologia Pediatrica presso il Centro Medico Hadassah. Dopo essersi laureato presso la Facoltà di Pediatria dell'Università Medica in Russia, il medico ha completato una residenza pediatrica e una borsa di studio in emato-oncologia pediatrica al Rambam. Ulteriore specializzazione ha incluso una borsa di studio in trapianto di midollo osseo pediatrico presso l'Ospedale per Bambini Malati di Toronto, Canada.<\/p>

Il medico è membro del consiglio della Società Israeliana di Emato-Oncologia Pediatrica e membro delle società europee e americane di BMT. Attivamente coinvolto nell'insegnamento, il medico ha pubblicato diversi articoli sui trapianti di midollo osseo pediatrico.<\/p>

Il medico è un oncoematologo esperto specializzato nel trattamento dei tumori del sangue e dei disturbi correlati. Con un focus su terapie innovative e cure personalizzate per i pazienti, il medico ha contribuito in modo significativo ai progressi nel campo. Il medico è affiliato a diverse istituzioni mediche di primo piano e ha pubblicato numerosi articoli di ricerca su riviste peer-reviewed.<\/p>

Il medico è anche attivamente coinvolto in studi clinici che mirano a migliorare i risultati per i pazienti con malignità ematologiche. Certificato in ematologia e oncologia, il medico è riconosciuto per la sua esperienza sia nella pratica clinica che nella ricerca.<\/p>

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Responsabile del più grande programma di trapianto di midollo osseo in Italia, eseguendo oltre 90 trapianti allogenici all'anno presso il San Raffaele. Uno dei principali specialisti di linfoma del paese.

• Guida l'Unità di Trapianto di Midollo Osseo dal 2006
• Specializzato in ematologia e medicina interna presso l'Università di Milano
• Ha pubblicato oltre 70 studi sui trapianti e sui tumori del sangue
• Membro della Società Europea per il Trapianto di Sangue e Midollo

Il Prof. Dr. Serdar Bedii Omay ha pubblicato oltre 65 articoli scientifici sull'ematologia e il trapianto di midollo osseo, con un'ampia esperienza nel settore.

• Formazione presso la Facoltà di Medicina di Mie in Giappone in ematologia molecolare
• Professore di Ematologia presso le Università di Ege e Karadeniz Teknik
• Specializzato in medicina interna ed ematologia dal 1990
• Autore di 112 articoli per congressi e di 34 presentazioni a conferenze

Direttore dell'Unità Linfomi presso il San Raffaele – Il Prof. Ferreri ha fondato la Fondazione Italiana Linfoma per studi clinici avanzati.

• Vice Direttore di Ematologia Oncologica con oltre 20 anni di esperienza
• Autore di oltre 300 articoli sul trattamento dei linfomi
• Specializzato nella ricerca sui linfomi non-Hodgkin
• Membro dell'Associazione Europea di Ematologia e della Società Americana di Ematologia